Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198658 | 0.87 | ALDH1A1 (0.50) | HCAR2ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL21202163 | 0.84 | TSHR (0.56) | HCAR2ALDH1A1TSHRLMNA | |
| SCHEMBL10777181 | 0.84 | TSHR (0.56) | HCAR2ALDH1A1TSHRLMNA | |
| SCHEMBL138475 | 0.83 | HCAR2 (0.48) | HCAR2ALDH1A1GAASMN1; SMN2TSHR | |
| SCHEMBL2294428 | 0.81 | ALDH1A1 (0.43) | ALDH1A1GAASMN1; SMN2TSHRLMNA | |
| SCHEMBL19262246 | 0.80 | DGAT1 (0.31) | GAACA12CA1 | |
| Water SCHEMBL27557216 | 0.80 | HCAR2 (0.46) | HCAR2ALDH1A1GAASMN1; SMN2TSHR | |
| SCHEMBL4736567 | 0.79 | HCAR2 (0.39) | HCAR2ALDH1A1TSHRLMNAESR1 | |
| SCHEMBL78520 | 0.77 | DGAT1 (0.46) | ALDH1A1GAASMN1; SMN2TSHRCHRM1 | |
| SCHEMBL9267222 | 0.77 | NPSR1 (0.32) | TDP1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786115-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-08-31 | — | — | US | disclosed |
| US-20080146566-A1 | Amide Derivatives | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1915350-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1831174-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007020411-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006067444-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146566-A1 | Amide Derivatives | IL6, IL1B, IL1A | HCAR2 118/4885ALDH1A1 327/4885GAA 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.